Qi Q, Han X, Tang C
Biomed Res Int. 2022; 2022:1164355.
PMID: 36132087
PMC: 9484888.
DOI: 10.1155/2022/1164355.
Salchow J, Strunk M, Niels T, Steck J, Minto C, Baumann F
Integr Cancer Ther. 2021; 20:15347354211037955.
PMID: 34590926
PMC: 8488411.
DOI: 10.1177/15347354211037955.
Galantino M, Tiger R, Brooks J, Jang S, Wilson K
Integr Cancer Ther. 2019; 18:1534735419850627.
PMID: 31131640
PMC: 6537287.
DOI: 10.1177/1534735419850627.
Tenti S, Giordano N, Cutolo M, Giannini F, Fioravanti A
Medicine (Baltimore). 2019; 98(13):e15052.
PMID: 30921233
PMC: 6455664.
DOI: 10.1097/MD.0000000000015052.
Chan A, de Boer R, Gan A, Willsher P, Martin R, Zissiadis Y
Support Care Cancer. 2017; 25(12):3785-3791.
PMID: 28691132
DOI: 10.1007/s00520-017-3810-9.
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Stearns V, Chapman J, Ma C, Ellis M, Ingle J, Pritchard K
J Clin Oncol. 2014; 33(3):265-71.
PMID: 25512454
PMC: 4289722.
DOI: 10.1200/JCO.2014.57.6926.
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.
Fusi C, Materazzi S, Benemei S, Coppi E, Trevisan G, Marone I
Nat Commun. 2014; 5:5736.
PMID: 25484020
PMC: 4268712.
DOI: 10.1038/ncomms6736.
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Mao J, Farrar J, Bruner D, Zee J, Bowman M, Seluzicki C
Cancer. 2014; 120(23):3744-51.
PMID: 25077452
PMC: 4239308.
DOI: 10.1002/cncr.28917.
Undesirable effects related to oral antineoplastic drugs: comparison between patients' internet narratives and a national pharmacovigilance database.
Pages A, Bondon-Guitton E, Montastruc J, Bagheri H
Drug Saf. 2014; 37(8):629-37.
PMID: 25027671
DOI: 10.1007/s40264-014-0203-6.
A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use.
Mao J, Xie S, Farrar J, Stricker C, Bowman M, Bruner D
Eur J Cancer. 2013; 50(2):267-76.
PMID: 24210070
PMC: 3972040.
DOI: 10.1016/j.ejca.2013.09.022.
Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Wang J, Lu K, Song Y, Xie L, Zhao S, Wang Y
PLoS One. 2013; 8(7):e68798.
PMID: 23894347
PMC: 3716812.
DOI: 10.1371/journal.pone.0068798.
Online discussion of drug side effects and discontinuation among breast cancer survivors.
Mao J, Chung A, Benton A, Hill S, Ungar L, Leonard C
Pharmacoepidemiol Drug Saf. 2013; 22(3):256-62.
PMID: 23322591
PMC: 4380018.
DOI: 10.1002/pds.3365.
A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy.
Robidoux A, Rich E, Bureau N, Mader S, Laperriere D, Bail M
Curr Oncol. 2011; 18(6):285-94.
PMID: 22184490
PMC: 3224030.
DOI: 10.3747/co.v18i6.909.
A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.
McDermott C, Hsieh A, Sweet E, Tippens K, McCune J
J Altern Complement Med. 2011; 17(11):1043-9.
PMID: 22087614
PMC: 3221507.
DOI: 10.1089/acm.2010.0471.
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Shanmugam V, McCloskey J, Elston B, Allison S, Eng-Wong J
Breast Cancer Res Treat. 2011; 131(2):699-708.
PMID: 22076476
PMC: 3664236.
DOI: 10.1007/s10549-011-1849-8.
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Mao J, Su H, Feng R, Donelson M, Aplenc R, Rebbeck T
Breast Cancer Res. 2011; 13(1):R8.
PMID: 21251330
PMC: 3109575.
DOI: 10.1186/bcr2813.
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
Burstein H, Prestrud A, Seidenfeld J, Anderson H, Buchholz T, Davidson N
J Clin Oncol. 2010; 28(23):3784-96.
PMID: 20625130
PMC: 5569672.
DOI: 10.1200/JCO.2009.26.3756.
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Henry N, Pchejetski D, AHern R, Nguyen A, Charles P, Waxman J
Br J Cancer. 2010; 103(3):291-6.
PMID: 20606683
PMC: 2920022.
DOI: 10.1038/sj.bjc.6605768.
Update on the use of aromatase inhibitors in early-stage breast cancer.
Kesisis G, Makris A, Miles D
Breast Cancer Res. 2009; 11(5):211.
PMID: 19889200
PMC: 2790854.
DOI: 10.1186/bcr2410.
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
Mao J, Stricker C, Bruner D, Xie S, Bowman M, Farrar J
Cancer. 2009; 115(16):3631-9.
PMID: 19517460
PMC: 3569524.
DOI: 10.1002/cncr.24419.
